source
- Novartis signs up to $900 million deal with China's BoomRay for preclinical radioligand therapyNovartis has licensed a preclinical radioligand therapy from BoomRay Pharmaceuticals, a Suzhou‑based biotech, in a deal that could be worth up to $900 million. The agreement includes an undisclose…
- Boston biotech seed funding drops 40% as investors favor later-stage firmsBoston remains the world’s largest biotech hub, but early‑stage startups are feeling a sharp squeeze in capital. The average seed round for a pre‑clinical company in Massachusetts fell to $4.65 mi…